| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mech...
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mecha...
Guggenheim analyst Brad Canino assumes ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $18.
JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target fro...
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price ta...
Guggenheim analyst Michael Schmidt reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $18 price target.
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and ann...